A literature-based meta-analysis taxane-based doublet versus single-agent taxane chemotherapy in patients with advanced breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 6, 2011, Pages 1005-1013

  Xu, Hong Bin ^a   Xu, Qing ^a   Li, Ling ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Advanced; Breast cancer; Doublet regimen; Meta analysis; Taxane

Indexed keywords

CAPECITABINE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 79959708906     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-010-0967-8     Document Type: Article

References (44)

1. Aihara T, Kim Y, Takatsuka Y (2002) Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 13:286-292 (Pubitemid 34704982)
2. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Janusz Rolski AP, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O'Shaughnessy J (2008) Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26:3950-3957
3. Baltali E, Altundag K, Ozisik Y, Guler N, Tekuzman G (2004) Weekly paclitaxel in pretreated metastatic breast cancer: retrospective analysis of 52 patients. Tohoku J Exp Med 203:205-210 (Pubitemid 39162087)
4. Bergh J, Jonsson PE, Glimelius B, Nygren P (2001) A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 40:253-281 (Pubitemid 32590835)
5. Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P, Assadourian S (2002) Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87:1210-1215 (Pubitemid 36009124)
6. Bontenbal M, Creemers GJ, Braun HJ, de Boer AC, Janssen JT, Leys RB, Ruit JB, Goey SH, van der Velden PC, Kerkhofs LG, Schothorst KL, Schmitz PI, Bokma HJ, Verweij J, Seynaeve C (2005) Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a dutch community setting trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 23:7081-7088
7. Bria E, Giannarelli D, Felici A, Peter WP, Nistico C, Vanni B, Cuppone F, Cognetti F, Terzoli E (2005) Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Cancer 103:672-679 (Pubitemid 40216393)
8. Bullock K, Blackwell K (2008) Clinical efficacy of taxane-trastuzumab combination regimen for HER-2-positive metastatic breast cancer. Oncologist 13:515-525 (Pubitemid 351872869)
9. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212-1219 (Pubitemid 30159838)
10. Case LD, Kimmick G, Paskett ED, Lohman K, Tucker R (2002) Interpreting measures of treatment effect in cancer clinical trials. Oncologist 7:181-187 (Pubitemid 34651220)
11. Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354 (Pubitemid 29368232)
12. D'Hondt R, Paridaens R, Wildiers H, Pauwelyn K, Thomas J, Dumez H, Van O, Allan T (2004) Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drugs 15:341-346 (Pubitemid 38526757)
13. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188 (Pubitemid 17189972)
14. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544-5552
15. Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, Kalofonos HP (2009) A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 115:87-99
16. Fumoleau P, Seidman AD, Trudeau ME, Chevallier B, Huinink WWTB (1997) Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert Opin Investing Drugs 6:1853-1865 (Pubitemid 27517589)
17. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104:1742-1750 (Pubitemid 41437440)
18. Gori S, Mosconi AM, Basurtol C, Cherubinil R, DeAngelis V, Tonato M, Colozza M (2002) Weekly paclitaxel in metastatic breast cancer patients: a phase II study. Tumori 88:470-473 (Pubitemid 36193895)
19. Hainsworth JD, Burris HA, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA (2001) Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 19:3500-3505
20. Horiguchi J, Oyama T, Koibuchi Y, Yokoe T, Takata D, Ikeda F, Nagaoka H, Rokutanda N, Nagaoka R, Ishikawa Y, Odawara H, Kikuchi M, Sato A, Iino Y, Takeyoshi I (2009) Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer. Anticancer Res 29:517-524
21. Icli E, Akbulut h, Uner A (2002) Paclitaxel (T) vs cisplatin + VP-16 (EP) in metastatic breast cancer patients treated with anthracyclines: a phase III randomized study. Turkish Oncology Group. Ann Oncol 13(Suppl 5):47
22. Icli F, Akbulut H, Uner A, Yalcin B, Baltali E, Altinbas M, Coşkun S, Komurcu S, Erkisi M, Demirkazik A, Senler FC, Sencan O, Büyükcelik A, Boruban C, Onur H, Zengin N, Sak SD (2005) Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. Br J Cancer 92:639-644 (Pubitemid 40460597)
23. Jackisch C, Eibach H, Knuth A (2000) Phase II trial of docetaxel weekly as dose dense treatment in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 18:417a
24. Jensen BV (2006) Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol 33(suppl 8):15-21
25. Kuroi K, Bando H, Saji S, Toi M (2003) Protracted administration of weekly docetaxel in metastatic breast cancer. Oncol Rep 10:1479-1484
26. Lombardi D, Crivellari D, Scuderi C, Magri MD, Spazzapan S, Sorio R, DiLauro V, Scalone S, Veronesi A (2004) Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori 90:285-288 (Pubitemid 38981273)
27. Maisano R, Mare M, Zavattieri M, Caristi N, Mesiti M, Scisca C, Latorre F (2003) Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? Anticancer Res 23:1923-1926
28. Mey U, Gorschluter M, Ziske C, Kleinschmidt R, Glasmacher A, Schmidt-Wolf IGH (2003) Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. Anticancer Drugs 14:233-238 (Pubitemid 36418943)
29. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676
30. Nabholtz JM, Thuerlimann B, Bezwoda WR, Melnychuk D, Dounma J, Vandenberg TA, Rapoport B, Rosso R, Trillet Lenoir V, Drbal J, Aapro MA, Alaki M, Murawsky M, Allesandro R (1997) Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. Oncology (Williston Park) 11(Suppl 8):25-30
31. Nabholtz JM, Senn HJ, Bezwoda W, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17:1413-1424 (Pubitemid 29220847)
32. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Hazel GV, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823 (Pubitemid 34651510)
33. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223
34. Ramos M, Gonzalez-Ageitos A, Amenedo M, Gonzalez-quintas A, Gamzo JL, Togores P, Losada G, Almanza C, Romero C, Gomez-martin C (2003) Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment. J Chemother 15:192-197 (Pubitemid 36609757)
35. Sato K, Inoue K, Saito T, Kai T, Mihara H, Okubo K, Koh J, Mochizuki H, Tabei T (2003) Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). Jpn J Clin Oncol 33:371-376 (Pubitemid 43102839)
36. Sawada N, Ishikawa T, Fukase Y et al (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 4:1013-1019 (Pubitemid 28183404)
37. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynaha ME, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361 (Pubitemid 28481632)
38. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm Sjovall M, Wist E, Valvere V, Anderson H, Bergh J (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35:1194-1201 (Pubitemid 29359178)
39. Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, Bogdanova NV, Manikhas GM, Oliynychenko GP, Chatikhine VA, Zhuang SH, Xiu L, Yuan ZL, Rackoff WR (2009) Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol 27:4522-4529
40. Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM (1996) Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14:422-428
41. Verma S, Maraninchi D, O'Shaughnessy J, Jamieson C, Jones S, Martin M, Mckendrick J, Miles D, Twelves C, Hornberger J (2005) Capecitabine plus docetaxel combination therapy. Cancer 103:2455-2465
42. Verma S, Dent S, Chow BJ, Rayson D, Safra T (2008) Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev 34:391-406
43. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717 (Pubitemid 10218041)
44. Wist EA, Sommer HH, Ostenstad B, Risberg T, Fjaestad K (2004) Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 43:11-14 (Pubitemid 38283167)